Deep learning-based classification of kidney transplant pathology: a retrospective, multicentre, proof-of-concept study

Jesper Kers(Leiden University Medical Center), Roman D. Bülow(RWTH Aachen University), Barbara M. Klinkhammer(Universitätsklinikum Aachen), Gerben E. Breimer(University Medical Center Utrecht), Francesco Fontana(Amsterdam University Medical Centers), Adeyemi Adefidipe Abiola(University of Amsterdam), Rianne Hofstraat(University of Amsterdam), Garry L. Corthals(Amsterdam University Medical Centers), Hessel Peters‐Sengers(Amsterdam University Medical Centers), Sonja Djudjaj(RWTH Aachen University), Saskia von Stillfried(RWTH Aachen University), David L. Hölscher(RWTH Aachen University), Tobias T. Pieters(University Medical Center Utrecht), Arjan D. van Zuilen(University Medical Center Utrecht), Fréderike J. Bemelman(Amsterdam University Medical Centers), Azam Nurmohamed(Amsterdam University Medical Centers), Maarten Naesens(KU Leuven), Joris J. T. H. Roelofs(Amsterdam University Medical Centers), Sandrine Florquin(Amsterdam University Medical Centers), Jürgen Floege(Universitätsklinikum Aachen), Tri Q. Nguyen(University Medical Center Utrecht), Jakob Nikolas Kather(RWTH Aachen University), Peter Boor(RWTH Aachen University)
The Lancet Digital Health
November 15, 2021
Cited by 119Open Access
Full Text

Abstract

BACKGROUND: Histopathological assessment of transplant biopsies is currently the standard method to diagnose allograft rejection and can help guide patient management, but it is one of the most challenging areas of pathology, requiring considerable expertise, time, and effort. We aimed to analyse the utility of deep learning to preclassify histology of kidney allograft biopsies into three main broad categories (ie, normal, rejection, and other diseases) as a potential biopsy triage system focusing on transplant rejection. METHODS: We performed a retrospective, multicentre, proof-of-concept study using 5844 digital whole slide images of kidney allograft biopsies from 1948 patients. Kidney allograft biopsy samples were identified by a database search in the Departments of Pathology of the Amsterdam UMC, Amsterdam, Netherlands (1130 patients) and the University Medical Center Utrecht, Utrecht, Netherlands (717 patients). 101 consecutive kidney transplant biopsies were identified in the archive of the Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany. Convolutional neural networks (CNNs) were trained to classify allograft biopsies as normal, rejection, or other diseases. Three times cross-validation (1847 patients) and deployment on an external real-world cohort (101 patients) were used for validation. Area under the receiver operating characteristic curve (AUROC) was used as the main performance metric (the primary endpoint to assess CNN performance). FINDINGS: Serial CNNs, first classifying kidney allograft biopsies as normal (AUROC 0·87 [ten times bootstrapped CI 0·85-0·88]) and disease (0·87 [0·86-0·88]), followed by a second CNN classifying biopsies classified as disease into rejection (0·75 [0·73-0·76]) and other diseases (0·75 [0·72-0·77]), showed similar AUROC in cross-validation and deployment on independent real-world data (first CNN normal AUROC 0·83 [0·80-0·85], disease 0·83 [0·73-0·91]; second CNN rejection 0·61 [0·51-0·70], other diseases 0·61 [0·50-0·74]). A single CNN classifying biopsies as normal, rejection, or other diseases showed similar performance in cross-validation (normal AUROC 0·80 [0·73-0·84], rejection 0·76 [0·66-0·80], other diseases 0·50 [0·36-0·57]) and generalised well for normal and rejection classes in the real-world data. Visualisation techniques highlighted rejection-relevant areas of biopsies in the tubulointerstitium. INTERPRETATION: This study showed that deep learning-based classification of transplant biopsies could support pathological diagnostics of kidney allograft rejection. FUNDING: European Research Council; German Research Foundation; German Federal Ministries of Education and Research, Health, and Economic Affairs and Energy; Dutch Kidney Foundation; Human(e) AI Research Priority Area of the University of Amsterdam; and Max-Eder Programme of German Cancer Aid.


Related Papers

No related papers found

Powered by citation graph analysis